Free Trial

Phathom Pharmaceuticals (PHAT) Insider Trading & Ownership

Phathom Pharmaceuticals logo
$6.06 -0.17 (-2.73%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$6.08 +0.02 (+0.25%)
As of 11/13/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Phathom Pharmaceuticals (NASDAQ:PHAT) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
9.33%
Number Of
Insiders Buying
(Last 3 Years)
3
Amount Of
Insider Buying
(Last 3 Years)
$126.72K
Number Of
Insiders Selling
(Last 3 Years)
5
Amount Of
Insider Selling
(Last 3 Years)
$31.10M
Get PHAT Insider Trade Alerts

Want to know when executives and insiders are buying or selling Phathom Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PHAT Insider Buying and Selling by Quarter

Phathom Pharmaceuticals Insider and Congressional Trades History

Transaction Date
0 Results
Transaction DateInsiderBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/3/2025Sell524$13.51$7,079.24  
9/5/2025Sell461$12.09$5,573.49  
7/16/2025Sell1,692$8.36$14,145.12  
5/21/2025Buy3,780$3.86$14,590.80  
5/6/2025
Asit Parikh
Asit Parikh
Director
Buy5,000$2.60$13,000.00  
4/7/2025Sell3,678$4.55$16,734.90  
1/21/2025Sell7,886$6.59$51,968.74  
1/21/2025Sell6,583$6.59$43,381.97  
1/21/2025Sell19,109$6.59$125,928.31  
12/19/2024Sell1,118$8.00$8,944.00  
12/19/2024Sell1,291$8.00$10,328.00  
12/13/2024
Frank Karbe
Frank Karbe
Director
Buy12,500$7.93$99,125.00  
7/15/2024Sell10,901$11.72$127,759.72  
7/15/2024Sell4,325$11.72$50,689.00  
7/15/2024Sell33,848$11.72$396,698.56  
4/8/2024Sell3,435$11.10$38,128.50  
3/22/2024Sell16,851$9.11$153,512.61  
1/24/2024
Pharmaceutical Co Ltd Takeda
Major Shareholder
Sell3,703,703$8.10$29,999,994.30  
1/19/2024Sell6,307$7.75$48,879.25  
(Data available from 1/1/2013 forward)

PHAT Insider Trading Activity - Frequently Asked Questions

The list of insiders at Phathom Pharmaceuticals includes Asit Parikh, Azmi Nabulsi, Frank Karbe, James N Topper, Molly Henderson, Pharmaceutical Co Ltd Takeda, Robert Charles Breedlove, and Terrie Curran. Learn more on insiders at PHAT.

9.33% of Phathom Pharmaceuticals stock is owned by insiders. Learn more on PHAT's insider holdings.

The following insiders have purchased PHAT shares in the last 24 months: Asit Parikh ($13,000.00), Frank Karbe ($99,125.00), and James N Topper ($14,590.80).

Insiders have purchased a total of 21,280 PHAT shares in the last 24 months for a total of $126,715.80 bought.

The following insiders have sold PHAT shares in the last 24 months: Azmi Nabulsi ($60,912.74), Molly Henderson ($70,444.87), Robert Charles Breedlove ($26,797.85), and Terrie Curran ($125,928.31).

Insiders have sold a total of 42,342 Phathom Pharmaceuticals shares in the last 24 months for a total of $284,083.77 sold.



Insider trading data for NASDAQ:PHAT was last updated on 11/3/2025, the date of the most recent reported insider or congressional trade. New trades are added as they're reported.
From Our Partners